Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study

被引:15
作者
Dali, Christine, I [1 ,7 ]
Groeschel, Samuel [2 ]
Moldovan, Mihai [3 ,4 ]
Farah, Mohamed H. [5 ]
Kraegeloh-Mann, Ingeborg [2 ]
Wasilewski, Margaret [6 ,8 ]
Li, Jing [6 ]
Barton, Norman [6 ]
Krarup, Christian [3 ,4 ]
机构
[1] Rigshosp, Dept Clin Genet, Copenhagen, Denmark
[2] Univ Childrens Hosp Tubingen, Dept Neuropediat, Tubingen, Germany
[3] Rigshosp, Dept Clin Neurophysiol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
[4] Univ Copenhagen, Dept Neurosci, Copenhagen, Denmark
[5] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA
[6] Shire, Lexington, MA USA
[7] Orphazyme AS, Copenhagen, Denmark
[8] Summit Therapeut PLC, Cambridge, MA USA
关键词
GROSS MOTOR FUNCTION; ENZYME REPLACEMENT THERAPY; BLOOD-BRAIN-BARRIER; CEREBROSPINAL-FLUID; MOUSE MODEL; CELL TRANSPLANTATION; N-ACETYLASPARTATE; LEVELS CORRELATE; SYSTEM; SULFATIDE;
D O I
10.1002/acn3.51254
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease caused by deficient activity of arylsulfatase A (ASA), resulting in severe motor and cognitive dysfunction. This phase 1/2 study evaluated the safety and efficacy of intravenous (IV) recombinant human ASA (rhASA; HGT-1111, previously known as Metazym) in children with MLD.Methods: Thirteen children with MLD (symptom onset < 4 years of age) were enrolled in an open-label, nonrandomized, dose-escalation trial and received IV rhASA at 50, 100, or 200 U/kg body weight every 14 (+/- 4) days for 52 weeks (NCT00418561; NCT00633139). Eleven children continued to receive rhASA at 100 or 200 U/kg during a 24-month extension period (NCT00681811). Outcome measures included safety observations, changes in motor and cognitive function, and changes in nerve conduction and morphometry. ResultsThere were no serious adverse events considered related to IV rhASA. Motor function and developmental testing scores declined during the study in all dose groups; no significant differences were observed between groups. Nerve conduction studies and morphometric analysis indicated that peripheral nerve pathology did not worsen during the study in any dose group. InterpretationIV rhASA was generally well tolerated. There was no evidence of efficacy in preventing motor and cognitive deterioration, suggesting that IV rhASA may not cross the blood-brain barrier in therapeutic quantities. The relative stability of peripheral nerve function during the study indicates that rhASA may be beneficial if delivered to the appropriate target site and supports the development of rhASA for intrathecal administration in MLD.
引用
收藏
页码:66 / 80
页数:15
相关论文
共 46 条
[1]   Enzymes Approved for Human Therapy: Indications, Mechanisms and Adverse Effects [J].
Baldo, Brian A. .
BIODRUGS, 2015, 29 (01) :31-55
[2]   Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective [J].
Beerepoot, Shanice ;
Nierkens, Stefan ;
Boelens, Jaap Jan ;
Lindemans, Caroline ;
Bugiani, Marianna ;
Wolf, Nicole I. .
ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (01)
[3]   Lysosomal storage diseases and the blood-brain barrier [J].
Begley, David J. ;
Pontikis, Charles C. ;
Scarpa, Maurizio .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (16) :1566-1580
[4]  
Behrman RE, 2000, TXB PEDIAT
[5]   Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy [J].
Biffi, Alessandra ;
Montini, Eugenio ;
Lorioli, Laura ;
Cesani, Martina ;
Fumagalli, Francesca ;
Plati, Tiziana ;
Baldoli, Cristina ;
Martino, Sabata ;
Calabria, Andrea ;
Canale, Sabrina ;
Benedicenti, Fabrizio ;
Vallanti, Giuliana ;
Biasco, Luca ;
Leo, Simone ;
Kabbara, Nabil ;
Zanetti, Gianluigi ;
Rizzo, William B. ;
Mehta, Nalini A. L. ;
Cicalese, Maria Pia ;
Casiraghi, Miriam ;
Boelens, Jaap J. ;
Del Carro, Ubaldo ;
Dow, David J. ;
Schmidt, Manfred ;
Assanelli, Andrea ;
Neduva, Victor ;
Di Serio, Clelia ;
Stupka, Elia ;
Gardner, Jason ;
von Kalle, Christof ;
Bordignon, Claudio ;
Ciceri, Fabio ;
Rovelli, Attilio ;
Roncarolo, Maria Grazia ;
Aiuti, Alessandro ;
Sessa, Maria ;
Naldini, Luigi .
SCIENCE, 2013, 341 (6148) :864-U58
[6]   PEDIATRIC LUMBAR PUNCTURE AND CEREBROSPINAL FLUID ANALYSIS [J].
Bonadio, William .
JOURNAL OF EMERGENCY MEDICINE, 2014, 46 (01) :141-150
[7]   Intrathecal delivery of protein therapeutics to the brain: A critical reassessment [J].
Calias, Pericles ;
Banks, William A. ;
Begley, David ;
Scarpa, Maurizio ;
Dickson, Patricia .
PHARMACOLOGY & THERAPEUTICS, 2014, 144 (02) :114-122
[8]   Mutation Update of ARSA and PSAP Genes Causing Metachromatic Leukodystrophy [J].
Cesani, Martina ;
Lorioli, Laura ;
Grossi, Serena ;
Amico, Giulia ;
Fumagalli, Francesca ;
Spiga, Ivana ;
Filocamo, Mirella ;
Biffi, Alessandra .
HUMAN MUTATION, 2016, 37 (01) :16-27
[9]   Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy [J].
Dali, C. I. ;
Hanson, L. G. ;
Barton, N. W. ;
Fogh, J. ;
Nair, N. ;
Lund, A. M. .
NEUROLOGY, 2010, 75 (21) :1896-1903
[10]   Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1/2 clinical trial [J].
Dali, Christine, I ;
Sevin, Caroline ;
Kraegeloh-Mann, Ingeborg ;
Giugliani, Roberto ;
Sakai, Norio ;
Wu, James ;
Wasilewski, Margaret .
MOLECULAR GENETICS AND METABOLISM, 2020, 131 (1-2) :235-244